Immunophenotypic findings in acute myeloid leukemia with FLT3 internal tandem duplication

被引:0
|
作者
Muñoz, L [1 ]
Aventín, A [1 ]
Villamor, N [1 ]
Juncà, J [1 ]
Acebedo, G [1 ]
Domingo, A [1 ]
Rozman, M [1 ]
Torres, JP [1 ]
Tormo, M [1 ]
Nomdedéu, JF [1 ]
机构
[1] Hosp Santa Creu & Sant Pau, Hematol Lab, Barcelona 08025, Spain
关键词
FLT3 internal tandem duplication; acute myeloid leukemia; immunophenotype; karyotype; minimal residual disease;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives. The biological characteristics and prognostic significance of the internal tandem duplication of the FLT3 (FLT3/ITD) were investigated in a series of de novo acute myeloid leukemia (AML) patients. One hundred and fifty-six adult patients with AML were included in the study. FLT3/ITD was detected in 41 (26%) patients (FLT3/ITD+). Design and Methods. The main differences observed between the groups with and without FLT3/ITD: a higher leukocyte count, a raised percentage of a normal karyotype and a more frequent M5 FAB diagnosis in the FLT3/ITD+ patients. As regards the immunophenotypic characteristics the FLT3/ITD+ group very often expressed monocytic markers (CD36 and CD11b) and less commonly immature markers (CD34 and CD117). A promyelocytic-like immunophenotype pattern was also detected in a minority of these patients (4/36). Results. The FLT3/ITD+ patients had a shorter overall survival. a shorter event-free survival and a higher probability of relapse. Minimal residual disease (MRD) was investigated in the FLT3/ITD+ patients using flow cytometry. This technique had a sensitivity of 62% and a specificity of 83% in relapse prediction. Minimal residual disease analysis was hampered by the low number of patients with detectable aberrant immunophenotype. Interpretation and Conclusions. A high frequency of changes in the phenotype and/or genotype pattern between diagnosis and relapse was detected (5/6). FLT3/ITD is a frequent molecular lesion in de novo adult AML and seems to be associated with momnocytic differentaition, a high leukocyte count and a poor prognosis. Immunophenotype and genotype patterns observed at relapse suggest that the FLT3/ITD+ blasts may be genetically unstable and prone to clonal evolution. FLT3/ITD may not be a suitable target for minimal residual disease studies. (C) 2003, Ferrata Storti Foundation.
引用
收藏
页码:637 / 645
页数:9
相关论文
共 50 条
  • [31] Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia
    Bibault, Jean-Emmanuel
    Figeac, Martin
    Helevaut, Nathalie
    Rodriguez, Celine
    Quief, Sabine
    Sebda, Sheherazade
    Renneville, Aline
    Nibourel, Olivier
    Rousselot, Philippe
    Gruson, Berengere
    Dombret, Herve
    Castaigne, Sylvie
    Preudhomme, Claude
    ONCOTARGET, 2015, 6 (26) : 22812 - 22821
  • [32] Tandem Duplication PCR: An Ultrasensitive Assay for the Detection of Internal Tandem Duplications of the FLT3 Gene
    Lin, Ming-Tseh
    Tseng, Li-Hui
    Beierl, Katie
    Hsieh, Antony
    Thiess, Michele
    Chase, Nadine
    Stafford, Amanda
    Levis, Mark J.
    Eshleman, James R.
    Gocke, Christopher D.
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2013, 22 (03) : 149 - 155
  • [33] FLT3 Inhibitors in the Management of Acute Myeloid Leukemia
    Zappone, E.
    Defina, M.
    Aprile, L.
    Bartalucci, G.
    Gozzetti, A.
    Bocchia, M.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2017, 17 (08) : 1028 - 1032
  • [34] Targeting FLT3 Mutations in Acute Myeloid Leukemia
    El Fakih, Riad
    Rasheed, Walid
    Hawsawi, Yousef
    Alsermani, Maamoun
    Hassanein, Mona
    CELLS, 2018, 7 (01)
  • [35] Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3
    Fukuda, Seiji
    Singh, Pratibha
    Moh, Akira
    Abe, Mariko
    Conway, Edward M.
    Boswell, H. Scott
    Yamaguchi, Seiji
    Fu, Xin-Yuan
    Pelus, Louis M.
    BLOOD, 2009, 114 (02) : 394 - 403
  • [36] A review of FLT3 inhibitors in acute myeloid leukemia
    Zhao, Jennifer C.
    Agarwal, Sonal
    Ahmad, Hiba
    Amin, Kejal
    Bewersdorf, Jan Philipp
    Zeidan, Amer M.
    BLOOD REVIEWS, 2022, 52
  • [37] An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape
    Bystrom, Rebecca
    Levis, Mark J.
    CURRENT ONCOLOGY REPORTS, 2023, 25 (04) : 369 - 378
  • [38] Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors
    Elshoury, Amro
    Przespolewski, Amanda
    Baron, Jeffrey
    Wang, Eunice S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (03) : 273 - 286
  • [39] Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia
    Wang, Eunice S.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2019, 32 (02) : 154 - 162
  • [40] Clonal Dynamics and Relapse Risk Revealed by High-Sensitivity FLT3-Internal Tandem Duplication Detection in Acute Myeloid Leukemia
    Oduro Jr, Kwadwo Asare
    Spivey, Theresa
    Moore, Erika M.
    Meyerson, Howard
    Yoest, Jennifer
    Tomlinson, Benjamin
    Beck, Rose
    Alouani, David
    Sadri, Navid
    MODERN PATHOLOGY, 2024, 37 (09)